Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase In Chronic Liver Disease And Cirrhosis-Related Deaths Marking These As Ninth Leading Cause Of Death In U.S.
Portfolio Pulse from Benzinga Newsdesk
Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc. (NYSE:BHC), has released its third edition of the Liver Health Trends Report. The report shows a 9% increase in chronic liver disease (CLD) and cirrhosis mortality, making these the ninth leading cause of death in the U.S. in 2021. The report also highlights ongoing disparities in CLD care, including a shortage of liver specialists in rural areas. The report is based on a survey of 400 health care providers, qualitative interviews, and secondary research from peer-reviewed publications.
October 10, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The report released by Salix Pharmaceuticals, a subsidiary of Bausch Health Companies, could potentially increase awareness of the company's focus on liver health, potentially leading to increased demand for its products and services.
The report highlights the increasing prevalence of chronic liver disease and the need for specialized care, which could potentially increase the demand for Salix's products and services. This could have a positive impact on Bausch Health's revenues in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100